Elijah W. Muriithi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elijah W. Muriithi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- David J Wheatley
University of Glasgow, Royal Infirmary, Glasgow, UK
3 shared publications Philip R Belcher
University of Glasgow, Department of Cardiac Surgery, The Royal Infirmary, 10 Alexandra Parade, Glasgow, Scotland G31 2ER, United Kingdom
3 shared publicationsL Raco
2 shared publicationsM A Chaudhry
University of Glasgow, Department of Cardiac Surgery, Royal Infirmary, UK
2 shared publications- Stephen P. Day
University of the West of Scotland
2 shared publications David J Wheatley
1 shared publication
Latest Publications
- 1 September 2001
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 72 (3) , 982
Platelet aggregates and cardiopulmonary bypass: Reply
- 1 September 2001
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 72 (3) , 982
Platelet aggregates and cardiopulmonary bypass: Reply
- Open Access
- 1 July 2001
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 72 (1) , 320-1
Heparin and platelet function.
- 1 July 2001
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 72 (1) , 320-1
Open AccessHeparin and platelet function.
- 1 January 2001
- Published by Taylor & Francis in Platelets
- Vol. 12 (1) , 34-36
Platelet aggregatory responses to low-dose collagen are maintained in hirudin-anticoagulated whole blood for 24 h when stored at room temperature
- 1 January 2001
- Published by Taylor & Francis in Platelets
- Vol. 12 (1) , 34-36
Platelet aggregatory responses to low-dose collagen are maintained in hirudin-anticoagulated whole blood for 24 h when stored at room temperature
- 1 September 2000
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 120 (3) , 538-543
The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass
- 1 September 2000
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 120 (3) , 538-543
The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass
- 1 June 2000
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 69 (6) , 1827-1832
Heparin-induced platelet dysfunction and cardiopulmonary bypass
- 1 June 2000
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 69 (6) , 1827-1832
Heparin-induced platelet dysfunction and cardiopulmonary bypass
- 1 May 2000
- Vol. 9 (3) , 429
Porcine versus pericardial bioprostheses: eleven-year follow up of a prospective randomized trial.
There is renewed interest in the pericardial heart valve as an alternative to the porcine bioprosthesis. The long-term results of a randomized trial comparing a second-generation pericardial valve against a well-tested porcine bioprosthesis are presented. Seven-year follow up has been reported previously. Production of the Bioflo pericardial prosthesis used in this trial was discontinued due to fears related to bovine spongiform encephalopathy. Between February 1987 and March 1990, 170 patients undergoing aortic (AVR) or mitral (MVR) valve replacement were assigned randomly to receive either the Bioflo pericardial bioprosthesis or the Carpentier-Edwards (CE) supra-annular porcine bioprosthesis. Eighty-five patients received 93 Bioflo valves (46 AVR, 31 MVR, eight AVR+MVR), and the remaining 85 received 99 CE valves (48 AVR, 23 MVR, 14 AVR+MVR). Mean patient age was 61.0 years (range: 38-77 years) for the Bioflo group and 62.1 years (range: 41-77 years) for the CE group. Current follow up is 100% complete and totals 1,391 patient-years; mean +/- SD follow up was 8.2 +/- 3.4 years (maximum 12.2 years). The operative mortality rate was 4.12%. There were 70 patients still at risk at 11 years (31 Bioflo, 39 CE); of these, 91.4% were in NYHA classes I/II. No significant difference in survival or valve-related complications was seen between the groups. Mean (+/- SEM) survival at 11 years was 41.4 +/- 6.8% in the Bioflo group and 55.3 +/- 6.8% in the CE group (p = 0.15). There were 16 valve-related deaths (nine in the Bioflo group, seven in the CE group). At 11 years, freedom from valve-related mortality was 89.5 +/- 3.9% for the Bioflo group and 91.0 +/- 3.5% for the CE group (p = 0.4). Valve position had no impact on survival. At 11 years, freedom from structural valve deterioration was 83.9 +/- 5.4% and 87.5 +/- 4.2% in the Bioflo and CE groups, respectively (p = 0.9). Over the 11-year period of follow up, clinical performance of the Bioflo pericardial valve was comparable with that of the Carpentier-Edwards supra-annular porcine bioprosthesis. No difference was apparent between the two valve types when implanted in either the aortic or the mitral position.
- 1 May 2000
- Vol. 9 (3) , 429
Porcine versus pericardial bioprostheses: eleven-year follow up of a prospective randomized trial.
There is renewed interest in the pericardial heart valve as an alternative to the porcine bioprosthesis. The long-term results of a randomized trial comparing a second-generation pericardial valve against a well-tested porcine bioprosthesis are presented. Seven-year follow up has been reported previously. Production of the Bioflo pericardial prosthesis used in this trial was discontinued due to fears related to bovine spongiform encephalopathy. Between February 1987 and March 1990, 170 patients undergoing aortic (AVR) or mitral (MVR) valve replacement were assigned randomly to receive either the Bioflo pericardial bioprosthesis or the Carpentier-Edwards (CE) supra-annular porcine bioprosthesis. Eighty-five patients received 93 Bioflo valves (46 AVR, 31 MVR, eight AVR+MVR), and the remaining 85 received 99 CE valves (48 AVR, 23 MVR, 14 AVR+MVR). Mean patient age was 61.0 years (range: 38-77 years) for the Bioflo group and 62.1 years (range: 41-77 years) for the CE group. Current follow up is 100% complete and totals 1,391 patient-years; mean +/- SD follow up was 8.2 +/- 3.4 years (maximum 12.2 years). The operative mortality rate was 4.12%. There were 70 patients still at risk at 11 years (31 Bioflo, 39 CE); of these, 91.4% were in NYHA classes I/II. No significant difference in survival or valve-related complications was seen between the groups. Mean (+/- SEM) survival at 11 years was 41.4 +/- 6.8% in the Bioflo group and 55.3 +/- 6.8% in the CE group (p = 0.15). There were 16 valve-related deaths (nine in the Bioflo group, seven in the CE group). At 11 years, freedom from valve-related mortality was 89.5 +/- 3.9% for the Bioflo group and 91.0 +/- 3.5% for the CE group (p = 0.4). Valve position had no impact on survival. At 11 years, freedom from structural valve deterioration was 83.9 +/- 5.4% and 87.5 +/- 4.2% in the Bioflo and CE groups, respectively (p = 0.9). Over the 11-year period of follow up, clinical performance of the Bioflo pericardial valve was comparable with that of the Carpentier-Edwards supra-annular porcine bioprosthesis. No difference was apparent between the two valve types when implanted in either the aortic or the mitral position.
- 1 February 2000
- Vol. 11 (1)
Quantitative detection of platelet aggregates in whole blood without fixation.
- 1 February 2000
- Vol. 11 (1)
Quantitative detection of platelet aggregates in whole blood without fixation.
- 1 January 2000
- Published by Taylor & Francis in Platelets
- Vol. 11 (1) , 33-37
Quantitative detection of platelet aggregates in whole blood without fixation
Platelet counting detects lesser degrees of platelet aggregation than conventional aggregometry. In order to prevent progressive platelet aggregation or disaggregation after sampling it is customary to fix blood samples. However fixation may introduce other artefacts. We first compared stability of platelet counts in EDTA-, citrate- and r-hirudin-anticoagulated blood from healthy volunteers. Second, the stability of platelet counts in unfixed EDTA- and hirudin-anticoagulated blood was compared with glutaraldehyde-fixed blood in the same anticoagulants. Third, the effect of in vivo heparin administration on platelet counts in EDTA- and hirudin-anticoagulated blood was studied. Platelet counts within 2 h of collection were significantly higher in EDTA- than in hirudin- or citrate-anticoagulated blood (P = 0.002 vs. hirudin and P = 0.001 vs. citrate). Twenty-four hour counts in hirudin and EDTA were unchanged (P = 0.3 and P = 0.2, respectively, vs. earlier counts). Counts in citrate increased significantly (P = 0.007; n = 10). Platelet counts in fixed blood did not differ significantly from those in unfixed blood. Heparin administered for cardiopulmonary bypass reduced platelet counts in hirudin-anticoagulated blood from (mean +/- 1 standard deviation) 180 +/- 45 to 162 +/- 30 x 10(9) l-1 (P = 0.01; n = 14), without significantly lowering counts with EDTA-anticoagulation, consistent with increased platelet aggregation. Hirudin and EDTA provided stable platelet counts, suggesting that fixation is unnecessary.
- 1 January 2000
- Published by Taylor & Francis in Platelets
- Vol. 11 (1) , 33-37
Quantitative detection of platelet aggregates in whole blood without fixation
Platelet counting detects lesser degrees of platelet aggregation than conventional aggregometry. In order to prevent progressive platelet aggregation or disaggregation after sampling it is customary to fix blood samples. However fixation may introduce other artefacts. We first compared stability of platelet counts in EDTA-, citrate- and r-hirudin-anticoagulated blood from healthy volunteers. Second, the stability of platelet counts in unfixed EDTA- and hirudin-anticoagulated blood was compared with glutaraldehyde-fixed blood in the same anticoagulants. Third, the effect of in vivo heparin administration on platelet counts in EDTA- and hirudin-anticoagulated blood was studied. Platelet counts within 2 h of collection were significantly higher in EDTA- than in hirudin- or citrate-anticoagulated blood (P = 0.002 vs. hirudin and P = 0.001 vs. citrate). Twenty-four hour counts in hirudin and EDTA were unchanged (P = 0.3 and P = 0.2, respectively, vs. earlier counts). Counts in citrate increased significantly (P = 0.007; n = 10). Platelet counts in fixed blood did not differ significantly from those in unfixed blood. Heparin administered for cardiopulmonary bypass reduced platelet counts in hirudin-anticoagulated blood from (mean +/- 1 standard deviation) 180 +/- 45 to 162 +/- 30 x 10(9) l-1 (P = 0.01; n = 14), without significantly lowering counts with EDTA-anticoagulation, consistent with increased platelet aggregation. Hirudin and EDTA provided stable platelet counts, suggesting that fixation is unnecessary.